These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 22664222)

  • 61. Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland.
    Clarke SC; Jefferies JM; Smith AJ; McMenamin J; Mitchell TJ; Edwards GF
    J Clin Microbiol; 2006 Apr; 44(4):1224-8. PubMed ID: 16597842
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods.
    Yildirim I; Stevenson A; Hsu KK; Pelton SI
    Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of conjugate 7-valent vaccination in Belgium: addressing methodological challenges.
    Hanquet G; Lernout T; Vergison A; Verhaegen J; Kissling E; Tuerlinckx D; Malfroot A; Swennen B; Sabbe M;
    Vaccine; 2011 Apr; 29(16):2856-64. PubMed ID: 21342667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Detection of Streptococcus pneumoniae and identification of pneumococcal serotypes by real-time polymerase chain reaction using blood samples from Italian children ≤ 5 years of age with community-acquired pneumonia.
    Marchese A; Esposito S; Coppo E; Rossi GA; Tozzi A; Romano M; Da Dalt L; Schito GC; Principi N
    Microb Drug Resist; 2011 Sep; 17(3):419-24. PubMed ID: 21510746
    [TBL] [Abstract][Full Text] [Related]  

  • 65. All-cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: A population-based study.
    Lau WCY; Bielicki J; Tersigni C; Saxena S; Wong ICK; Sharland M; Hsia Y
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):821-829. PubMed ID: 30993835
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
    Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
    Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A case report of parapneumonic pleural effusion caused by Streptococcus pneumoniae serotype 19A in a child immunized with 13-valent conjugate pneumococcal vaccine.
    Diawara I; Zerouali K; Elmdaghri N; Abid A
    BMC Pediatr; 2017 Apr; 17(1):114. PubMed ID: 28449653
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospective surveillance study of invasive pneumococcal disease among urban children in the Philippines.
    Capeding MR; Bravo L; Santos J; Kilgore PE; Kim SA; Balter I; Hubler R; Ye J; Moscariello M
    Pediatr Infect Dis J; 2013 Oct; 32(10):e383-9. PubMed ID: 23629024
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis.
    Andrade AL; Afonso ET; Minamisava R; Bierrenbach AL; Cristo EB; Morais-Neto OL; Policena GM; Domingues CMAS; Toscano CM
    PLoS One; 2017; 12(9):e0184204. PubMed ID: 28880953
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
    Byington CL; Korgenski K; Daly J; Ampofo K; Pavia A; Mason EO
    Pediatr Infect Dis J; 2006 Mar; 25(3):250-4. PubMed ID: 16511389
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine.
    Kaplan SL; Barson WJ; Lin PL; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Givner LB; Mason EO
    Pediatr Infect Dis J; 2013 Mar; 32(3):203-7. PubMed ID: 23558320
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance.
    Arifeen SE; Saha SK; Rahman S; Rahman KM; Rahman SM; Bari S; Naheed A; Mannan I; Seraji MH; Ahmed NU; Hassan MS; Huda N; Siddik AU; Quasem I; Islam M; Fatima K; Al-Emran H; Brooks WA; Baqui AH; Breiman RF; Sack D; Luby SP
    Clin Infect Dis; 2009 Mar; 48 Suppl 2():S103-13. PubMed ID: 19191605
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pneumococcal Vaccination and Pneumonia Associated With Pleural Effusion in a Pediatric Population.
    Bernaola E; Gil F; Herranz M; Gil-Setas A; Guevara M; Castilla J
    Pediatr Infect Dis J; 2018 Apr; 37(4):e87-e92. PubMed ID: 28938258
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months---selected U.S. regions, 2010--2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(43):1477-81. PubMed ID: 22048728
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
    Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
    Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clinical presentation of invasive pneumococcal disease in Spain in the era of heptavalent conjugate vaccine.
    de Sevilla MF; García-García JJ; Esteva C; Moraga F; Hernández S; Selva L; Coll F; Ciruela P; Planes AM; Codina G; Salleras L; Jordan I; Domínguez A; Muñoz-Almagro C
    Pediatr Infect Dis J; 2012 Feb; 31(2):124-8. PubMed ID: 22173137
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil.
    Afonso ET; Minamisava R; Bierrenbach AL; Escalante JJ; Alencar AP; Domingues CM; Morais-Neto OL; Toscano CM; Andrade AL
    Emerg Infect Dis; 2013 Apr; 19(4):589-97. PubMed ID: 23628462
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB; Grijalva CG; Arbogast PG; Talbot TR; Craig AS; Griffin MR; Schaffner W
    Pediatr Infect Dis J; 2013 Jun; 32(6):604-9. PubMed ID: 23348816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.